Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration-Primary End Point

The author(s) have no proprietary or commercial interest in any materials discussed in this article.